Form 4 for TXG 10x Genomics, Inc.
Accepted 2024-03-06 00:00:00 ET · period of report 2024-03-04 · accession 0001610717-24-000135 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-06 | 2024-03-04 | TXG | Saxonov Serge | CEO, Dir | S - Sale | $44.00 | -4,660 | 842.9K | -0.5% | -$205.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-03-04 | S | D | 4,660 | $44.00 | 842,900 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $43.9600 to $44.0401. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |